ReviewExpert opinion on therapeutic targets2016
Therapeutic targets for cholestatic liver injury.
Review in Expert opinion on therapeutic targets, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 49 citations in OpenAlex.
- Pictorial review of abdominopelvic diseases with elevated alpha-fetoprotein levels.Abdominal radiology (New York) · 2026Review
- Microbiota in cholestatic diseases: crosstalk among bile composition, the biliary microbiome, and host immunity.Frontiers in immunology · 2026Review
- Conjugated bile acid-driven CD14JHEP reports : innovation in hepatology · 2025Article
- Effect of Bile on Hemodynamics and Blood Micro-Rheological Parameters in Experimental Models of Bilhemia.Metabolites · 2024Article
- Bile acid-mediated signaling in cholestatic liver diseases.Cell & bioscience · 2023Review
- Effect of Percutaneous Biliary Drainage on Enzyme Activity of Serum Matrix Metalloproteinase-9 in Patients with Malignant Hilar Obstructive Hyperbilirubinemia.Medicina (Kaunas, Lithuania) · 2023Article
- Primary biliary cholangitis: molecular pathogenesis perspectives and therapeutic potential of natural products.Frontiers in immunology · 2023Review
- Article
- Inflammation-induced cholestasis in cancer cachexia.Journal of cachexia, sarcopenia and muscle · 2021Article
- Inflammation and Cell Death During Cholestasis: The Evolving Role of Bile Acids.Gene expression · 2019Review
- Cytotoxic and inflammatory effects of individual and combined exposure of HepG2 cells to zearalenone and its metabolites.Naunyn-Schmiedeberg's archives of pharmacology · 2019Article
- Biliary atresia combined with progressive familial intrahepatic cholestasis type 3: A case report and review of the literature.Medicine · 2019Review
- Baicalin Protects Against 17α-Ethinylestradiol-Induced CholestasisFrontiers in pharmacology · 2019Article
- Targeting HMGB1/TLR4 axis and miR-21 by rosuvastatin: role in alleviating cholestatic liver injury in a rat model of bile duct ligation.Naunyn-Schmiedeberg's archives of pharmacology · 2019Article
- Preventive effect of artemisinin extract against cholestasis induced via lithocholic acid exposure.Bioscience reports · 2018Article
- Danger-Associated Molecular Patterns (DAMPs): Molecular Triggers for Sterile Inflammation in the Liver.International journal of molecular sciences · 2018Review
- Serum and Hepatic Autofluorescence as a Real-Time Diagnostic Tool for Early Cholestasis Assessment.International journal of molecular sciences · 2018Article
- Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents.Liver international : official journal of the International Association for the Study of the Liver · 2018Article
- Sortilin 1 Loss-of-Function Protects Against Cholestatic Liver Injury by Attenuating Hepatic Bile Acid Accumulation in Bile Duct Ligated Mice.Toxicological sciences : an official journal of the Society of Toxicology · 2018Article
- Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response.JCI insight · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
introductionCholestasis is a reduction in bile flow that occurs during numerous pathologies. Blockage of the biliary tracts results in hepatic accumulation of bile acids or their conjugate bile salts. The molecular mechanisms behind liver injury associated with cholestasis are extensively studied, but not well understood. Multiple models of obstructive cholestasis result in a significant inflammatory infiltrate at the sites of necrosis that characterize the injury. AREAS COVERED: This review will focus on direct bile acid toxicity during cholestasis, bile acid signaling processes and on the development and continuation of inflammation during cholestasis, with a focus on novel proposed molecular mediators of neutrophil recruitment. While significant progress has been made on these molecular mechanisms, a continued focus on how cholestasis and the innate immune system interact is necessary to discover targetable therapeutics that might protect the liver while leaving global immunity intact. EXPERT OPINION: While bile acid toxicity likely occurs in humans and other mammals when toxic bile acids accumulate, persistent inflammation is likely responsible for continued liver injury during obstructive cholestasis. Targeting molecular mediators of inflammation may help prevent liver injury during acute cholestasis both in murine models and human patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.